CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novocure Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novocure Ltd
No. 4 The Forum, Grenville Street
Phone: +44 1534756700p:+44 1534756700 SAINT HELIER, JE2 4UF  Jersey Ticker: NVCRNVCR
Business Summary
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board William F.Doyle 62 5/11/2016 1/1/2009
Chief Executive Officer, Director AshleyCordova 46 6/4/2025 9/1/2020
Chief Financial Officer ChristophBrackmann 51 1/1/2025 1/1/2025
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
NovoCure GmbH Elektrastra?e 6 M?nchen Germany

Business Names
Business Name
NovoCure (Israel) Ltd.
Novocure Austria GmbH
Novocure Belgium S.r.l.
18 additional Business Names available in full report.

General Information
Number of Employees: 1,488 (As of 12/31/2024)
Outstanding Shares: 111,799,290 (As of 7/18/2025)
Shareholders: 17
Stock Exchange: NASD


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, August 30, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!